Clinical trial
Effect of Memantine on Functional Communication in Patients With Alzheimer's…
NCT00469456 · Forest Laboratories, Industry · Completed
Key facts
| NCT number | NCT00469456 |
|---|---|
| Title | Effect of Memantine on Functional Communication in Patients With Alzheimer's Disease |
| Official title | A Randomized, Double-Blind, Placebo-Controlled Evaluation of the Efficacy of Memantine on Functional Communication in Patients With Alzheimer's Disease (AD) |
| Lead sponsor | Forest Laboratories, Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Alzheimer's Disease |
| Intervention type | Drug |
| Interventions | Memantine, placebo |
| Enrollment | 265 |
| Start date | Apr 1, 2007 |
| Primary completion | Nov 1, 2008 |
| Completion | Nov 1, 2008 |
| First posted | May 4, 2007 |
| Last update posted | Dec 24, 2009 |
| Countries | Australia, New Zealand, South Africa |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: